

41


Dkt. 60388-A-PCT-US/JPW/GJG/JBC

Applicants: Mary Cismowski AND Emir Duzik

Serial No.: 09/709,103

Filed : November 8, 2000

Title : AGS PROTEINS AND NUCLEIC ACID MOLECULES AND USES THEREFOR



Group Art Unit: 1636

Examiner: D. Sullivan

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 25, 2003

S I R:

Transmitted herewith is an amendment to the above identified application.

Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been established by a verified statement previously submitted.

A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27 is enclosed.

x No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMEND- MENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE					FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY		
Total Claims	13	-	20	=	0	X	\$9	\$18	=	0	0		
Indepen- dent Claims	2	-	3	=	0	X	\$42.00	\$84.00	=	0	0		
Multiple Dependent Claim(s) Presented Yes <u>X</u> No							\$140	\$280	0	0	0		
							TOTAL ADDITIONAL FEE						\$ 0

*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

**If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

***If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

RECEIVED
SEP 03 2003
TECH CENTER 1636/1450

Applicants: Mary Cismowski and Emir Duzic

Serial No.: 09/709,103

Filed : November 8, 2000

Amendment Transmittal Letter

Page Two

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment of the number of claims as originally filed

____ Please charge Deposit Account No. 03-3125
in the amount of \$ _____. Three copies of this
sheet is enclosed.


X A check in the amount of \$ 930.00 is enclosed,
for a three-month extension of time.

X The Commissioner is hereby authorized to
charge payment of the following fees
associated with this communication or
credit any overpayment to Deposition
Account No. 03-3125. Three copies of
this sheet are enclosed.

X Any filing fees under 37 C.F.R.
§1.16 for the presentation of
extra claims.

X Any patent application
processing fees under 37 C.F.R.
§1.17.


Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this
correspondence is being deposited
this date with the U.S. postal
Service with sufficient postage as
first class mail in an envelope
addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 2313-1450

 8/25/03
Date
John P. White
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The statement in accordance with 37 C.F.R. 1.821 (f) filed 3/22/02
does not include a statement of "no new matter". (see 37 CFR 1.821(g)).

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY